Engflag

Omisec

Quick links to important sections

Omisec

Omisec_ES

Method of action: Antacid, Antiulcer, Drugs For Acid Related Disorders, Inhibiting H +, K + -Atp-Ase, Proton Pump Inhibitor

Treatment option: Duodenal Ulcer, Heartburn, Reflux, Esophageal Reflux, Reflux Esophagitis, Zollinger-Ellison Syndrome, Helicobacter Pylori, Esophagitis, Stomach Ulcer, Peptic Ulcer

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omisec

Omisec is a prescription medication designed to reduce the production of acid in the stomach. Its core identity is rooted in its potent chemical action as a gastric acid suppressant, making it a cornerstone treatment for various acid-related disorders.

Property Description
Active ingredient Omeprazole
Form Delayed-release capsule or tablet
Pharmacological class Proton Pump Inhibitor (PPI)
Common use Reduction of gastric acidity
Origin Synthetic organic compound

Defining Omisec: Classification and Composition

Omisec is classified as a Proton Pump Inhibitor (PPI), a designation that precisely describes its mechanism of action. The active ingredient, Omeprazole, is a synthetic organic compound that belongs to the substituted benzimidazole class. PPIs are distinguished by their ability to achieve a powerful and long-lasting suppression of acid secretion, an effect recognized for providing superior acid control compared to older drug classes.

The medication is available as a prescription-only medicine and is formulated as a single active ingredient product. Omisec is positioned to serve a broad target audience, including adults and certain pediatric patients, for conditions where sustained acid reduction is medically necessary.

Composition, Forms, and General Purpose

Omisec is supplied primarily for oral intake in the form of a delayed-release capsule or delayed-release tablet. This specialized delayed-release formulation is critical for its efficacy, as the active drug, Omeprazole, would otherwise be rapidly degraded and inactivated by stomach acid. The protective coating on the pellets ensures the drug remains intact until it reaches the small intestine for absorption and systemic action.

The general therapeutic purpose of Omisec is to achieve a consistent and substantial decrease in the stomach's acid environment. This sustained acid reduction is vital for allowing damaged tissue to heal, such as when managing a patient with ongoing symptoms of Gastroesophageal Reflux Disease (GERD). Omeprazole, as a PPI, is a well-established treatment for conditions characterized by gastric acid oversecretion.

Regulatory References

  1. Omeprazole - StatPearls

What side effects are possible with Omisec?

Possible Side Effects and Safety Information

Omisec's safety profile is documented by regulatory authorities, classifying potential side effects according to the physiological system affected and their reported frequency. This structured approach, based on clinical trials and post-marketing surveillance, helps define the medicine's risk profile.

Documented Adverse Reactions and Frequencies

Side effects are categorized based on their rate of occurrence in regulatory documents. The Common adverse reactions (affecting ge 1/100 to < 1/10 patients) primarily involve the gastrointestinal system and the central nervous system, including headache, abdominal pain, nausea, vomiting, diarrhea, and flatulence.

Adverse effects classified as Uncommon (ge 1/1,000 to < 1/100) include insomnia, dizziness, somnolence, and skin reactions such as dermatitis, rash, and urticaria.

Rare and Very Rare events involve more serious outcomes like leukopenia, severe hypersensitivity reactions (including anaphylaxis), and acute tubulointerstitial nephritis.

Contextual Safety Patterns

Specific safety concerns are noted in relation to the duration of treatment. Long-term use (e.g., one year or longer) is officially associated with an increased risk of osteoporosis-related fractures (hip, wrist, spine), Hypomagnesemia (low blood magnesium), and Cyanocobalamin (Vitamin B-12) deficiency.

Regulatory labeling also includes high-level constraints. Symptomatic response to therapy does not rule out the presence of an underlying gastric malignancy. Furthermore, the drug may interfere with the diagnosis of neuroendocrine tumors by increasing Chromogranin A (CgA) levels, requiring temporary cessation before testing.

Overdose and Emergency Response

Overdose and when to seek help

Official Manifestations and Severity

Omisec overdosage, as documented in official government regulatory sources, is typically associated with a transient symptom profile. The clinical manifestations reported often include Central Nervous System effects such as confusion and headache, along with specific signs like blurred vision. Systemic presentations documented include an unusually fast heartbeat, flushing, and unusual sweating. Gastrointestinal effects listed are dryness of the mouth, abdominal pain, nausea, vomiting, and diarrhea. Official prescribing information notes that symptoms are generally transient, and single high doses (up to 2,400 mg) have resulted in no serious outcome being reported in literature cited by regulatory bodies.

Emergency Action and Treatment Protocol

Immediate medical attention is mandated by regulatory documents in the event of an overdose. Individuals are required to get medical help or contact a Poison Control Center right away. The official prescribing information confirms that no specific antidote is known for Omisec overdosage. Consequently, the procedural steps defined in regulatory documents for overdose management are limited to symptomatic and supportive treatment administered to address the specific transient clinical signs that may be present.

Therapeutic Uses of Omisec

Omisec is prescribed for the supportive management of conditions associated with excessive production of stomach acid. The primary therapeutic goal is to help decrease acid levels, which may contribute to symptom relief and support the healing of the esophagus and stomach lining.

The medication is utilized for the short-term treatment of active duodenal and benign gastric ulcers, and for managing symptomatic gastroesophageal reflux disease (GERD). It is also indicated for the maintenance of healing in erosive esophagitis and for the long-term management of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome. Furthermore, it is a component of a regimen designed to help reduce the potential for duodenal ulcer recurrence associated with H. pylori bacteria.

Quick Fact: Relief for Acid Reflux Discomfort

Eligibility and Restrictions for Use

Official Eligibility Profile for Omisec (Omeprazole)

Eligibility Status Applicable Populations
Contraindicated Patients with known hypersensitivity to omeprazole, substituted benzimidazoles (the drug class), or any component of the formulation. Patients receiving concomitant treatment with certain antivirals, such as Nelfinavir or Rilpivirine-containing products, are also contraindicated [FDA, EMA].
Approved for Use Adults are approved for all labeled indications. Pediatric patients aged one year and older are approved for specific uses like symptomatic Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis (EE) [FDA].
Conditional/Caution Patients with severe hepatic impairment may require a dose reduction or special monitoring due to altered drug metabolism [FDA, NIH]. Use for long periods (e.g., over one year) requires caution and may be conditional upon monitoring for conditions like hypomagnesemia [EMA].
Use Not Established The safety and effectiveness of Omisec have not been established in infants less than one month of age [FDA].
Reproductive Status Pregnancy: Omisec may be used when the clinical benefit justifies the potential risk. Lactation: Use is generally not recommended by some authorities, while others advise caution and professional consultation [NIH, EMA].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Documentation Summary
Medicinal product categories with documented interactions HIV Antivirals, Antiplatelet agents, Antifungals, Anticoagulants, Immunosuppressants, Iron Salts.
Specific interacting medicines (if explicitly listed) Nelfinavir, Rilpivirine, Clopidogrel, Warfarin, Diazepam, Phenytoin, Tacrolimus, Ketoconazole, Rifampin, St. John’s Wort.
Mechanistic basis of interactions (only if stated in label) Inhibition of CYP2C19 enzyme; Gastric pH elevation (reduced absorption of pH-dependent drugs); P-glycoprotein (P-gp) inhibition (potential).
Timing-based interaction rules (if applicable) Diminished anti-platelet activity of Clopidogrel may occur even with 12 hours separation from Omeprazole.
Population-specific interaction notes (if applicable) CYP2C19 poor metabolizers demonstrate significantly higher systemic exposure to Omisec.
Interaction-related restrictions Co-administration is contraindicated with Nelfinavir and Rilpivirine. Avoid concomitant use with CYP inducers like Rifampin and St. John’s Wort.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration is contraindicated with Nelfinavir and Rilpivirine due to the risk of reduced plasma concentrations and loss of virologic response.
  • Omisec is an inhibitor of the CYP2C19 enzyme, which can increase the systemic exposure of substrates such as Diazepam, Phenytoin, and Cilostazol.
  • Omisec reduces the conversion of the prodrug Clopidogrel to its active metabolite, diminishing its anti-platelet activity even when separated by 12 hours.
  • The increase in gastric pH reduces the absorption of Ketoconazole, Itraconazole, and Atazanavir and requires monitoring for potential increases in the plasma levels of Digoxin.

Connection to the overall interaction profile: The official interaction structure for Omisec is defined by two core effects: inhibition of the CYP2C19 enzyme and a resulting increase in gastric pH. These mechanisms necessitate formal prohibitions, such as the contraindication with certain antivirals, and require mandated monitoring for substances like Warfarin and Tacrolimus to prevent alterations in their systemic exposure.

Mechanism of Action

Irreversible Blockade of the Gastric Proton Pump

Omisec's mechanism of action relies on a two-step activation cascade. The compound acts as a prodrug that concentrates within the highly acidic canaliculi of the gastric parietal cells. In this low pH environment, the molecule undergoes a chemical transformation, converting it into its active sulfenamide intermediate.

This intermediate then forms a stable, covalent bond with specific cysteine residues on the H^+/ K^+- ATPase enzyme system, also known as the proton pump. Since this enzyme represents the final common pathway for hydrochloric acid ( HCl) secretion, its irreversible inhibition halts the cellular mechanism of acid production.

Sustained Reduction of Gastric Acidity

This sustained blockade of active proton pumps leads directly to the primary system-level physiological consequence: a reduction in the concentration of gastric acid in the stomach lumen. This effect significantly raises the pH of the stomach contents, resulting in a non-acidic gastric environment. This process underlies the duration of the achieved acid suppression.

Dosage and Administration Information

Official Instructions for Omisec Administration

Omisec (omeprazole delayed-release) is administered orally and must be taken exactly as prescribed or directed on the non-prescription label to ensure the medicine is delivered correctly.

Dosing and Timing

Administration Detail Official Instruction
Route of Administration Oral (by mouth)
Timing Typically once daily (often in the morning). Must be taken before a meal.
Standard Dose Varies by condition; a common adult regimen is 20 mg once daily. Doses over 80 mg daily must be divided and given twice daily.
Duration of Use Short-term treatment may range from 4 to 8 weeks; non-prescription use is typically 14 consecutive days with a limit on repeating the course more often than once every four months.

Procedural Steps and Missed Doses

  • Swallowing Instructions: The delayed-release capsule or tablet must be swallowed whole with a glass of water. It is a mandatory requirement to not crush, chew, or split the capsule or tablet.
  • Alternative Administration: For individuals who cannot swallow the capsule whole, the capsule may be opened, and the granules inside can be emptied onto a tablespoon of soft, cool applesauce. This mixture must be swallowed immediately and should not be chewed.
  • Missed Dose Procedure: If a dose is missed, take it as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients must not take a double dose to compensate for a missed dose.

These official administration guidelines strictly govern the correct timing and method of use for Omisec, ensuring the delayed-release formulation performs as intended.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Research on Omisec, a proton pump inhibitor (PPI), has primarily focused on its effect on conditions related to gastric acid secretion. Studies investigated its action within the parietal cells of the stomach, where it works to inhibit the final step of acid production.

Clinical Trial Phases

Initial, small-scale Phase 1 trials evaluated the drug's safety profiles. Phase 2 trials then investigated various dosage levels and evaluated findings related to specific disease markers in patient groups. Phase 3 trials involved larger groups in comparative studies, further evaluating findings related to patient symptoms and gathering long-term data on changes in disease over time.

Findings in Acid-Related Disorders

Clinical research has explored outcomes in major acid-related conditions, including Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). Trials have assessed the drug's impact on reducing symptoms such as heartburn and promoting the healing of the esophageal and gastric lining in both adult and pediatric populations. Some studies have also examined its use in conditions of excessive acid production, such as Zollinger-Ellison syndrome.

Combination Use and Safety

Several studies investigated the drug's use as part of combination therapy with antibiotics for the eradication of Helicobacter pylori, a common cause of peptic ulcers. Research explored whether this combination was associated with better rates of bacterial clearance compared to antibiotic regimens alone.

Safety profiles were evaluated across a range of adult age groups and specific patient populations in the trials, providing data on potential effects associated with both short-term and long-term use.

How should Omisec be stored and disposed of?

How to Store and Dispose of Omeprazole (Omisec)

Official regulatory labeling dictates strict conditions for the storage and disposal of Omeprazole to maintain product stability and safety.

Required Storage Conditions

Omeprazole delayed-release capsules must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and should not be stored above 30 C. The medicine must be kept in its original container and the cap must be tightly closed to protect from light and moisture. Due to humidity concerns, Omeprazole should not be stored in a bathroom.

For child safety, the medication must be stored out of the sight and reach of children.

Stability and Disposal

If the product is supplied as a reconstituted suspension, it must be stored refrigerated at 2 C to 8 C (36 F to 45 F) and is only stable for a limited period, such as 28 days.

Disposal of unused or expired Omeprazole must be managed in accordance with local regulations and is typically handled via drug take-back programs or specific household disposal methods, as mandated by health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagEgypt

Equivalent of Omisec found in:

A-Z Index: